


GROWTH HORMONE AND INDUCTION OF OVULATION



Thesis

Submitted for Partial Fulfillment of
M.Sc. Degree in
"Obstetrics and Gynaecology"



61811
G.M

By

Ghamry Mahmoud Ahmed Saleh

M.B., B.Ch.
(Ain Shams University)

51834

Under Supervision of

Prof. Dr. Mohamed Nagy El-Makhzangy

Professor of Obstetrics and Gynaecology
Faculty of Medicine
Ain Shams University

Dr. Khaled Mohamed Aziz Diab

Lecturer in Obst. and Gyn.
Faculty of Medicine
Ain Shams University

Dr. Sanaa Eissa Hamed

Lecturer in Biochemistry
Faculty of Medicine
Ain Shams University

M. N. El-Makhzangy

Shereef El-Ghaly

**Faculty of Medicine
Ain Shams University
1993**

ACKNOWLEDGEMENT

It is my particular pleasure to thank Dr. Mohammed Nagy El-Makhzangy, Professor of Obstetrics and Gynaecology, Ain Shams University, for supervising this work. His encouragement and assistance were of major help. He has generously offered his support during the whole period of the present research, and thoroughly enriched the work with many enlightening ideas.

I also wish to extend my deep thanks to Dr. Khaled Diab, Lecturer in Obstetrics and Gynaecology, Ain Shams University, for his kind supervision and great help. I would not like to leave the present opportunity without emphasizing the benefit I have personally gained through his continuous counselling and guiding me.

I also wish to express my deep gratitude to Dr. Sanaa Eissa, Lecturer in Biochemistry at Faculty of Medicine, Ain Shams University, for being so helpful and advisor in the completion of growth hormone radioimmunoassay.

I also wish to address my sincere thanks to Dr. Karim Abd-El Maeboud, Lecturer in Obstetrics and Gynaecology, Ain Shams University, for suggesting the subject of this thesis.

I also convey my appreciation and gratitude to Dr. Hisham Radwan, for his valuable help in the ultrasonic folliculometry follow up which would not have been possible without his assistance and guidance.



Contents

	PAGE
INTRODUCTION	1
AIM OF THE WORK	4
REVIEW OF LITERATURE	5
■ Methods of Ovulation Induction	5
● Medical Methods	6
☐ Clomiphene Citrate	7
☐ Gonadotropins	19
☐ Prolactin-Inhibiting Agents	24
☐ Opiate Receptors Blockers (Antagonists)	31
☐ Cortisone Derivative	33
☐ Gonadotrophin Releasing Hormone (GnRH) and its Analogues	36
● Surgical Methods	40
☐ Wedge Resection of the Ovaries	40
☐ Laparoscopic Ovarian Electrocautery and Laser Vaporization	41
■ Local Modulators of ovarian Functions	43
● Steroidal Constituents	43
● Pituitary Peptides	45
● Non-Steroidal Constituents Related to Ovulatory Process	48
☐ Proteoglycans	48
☐ Plasminogen Activators (PA)	51
☐ Alpha-1-Antitrypsin, Fibrinogen and IgG in F.F.	52


● Non Steroidal Constituents Directly related to Oocyte Maturation	53
● Non-Steroidal Ovarian Inhibitor of Gn Secretion (FSH Mainly) = Inhibin or Folliculostatin	57
● Follicular Protein that Regulate Ovarian Response To Gn Stimulation	61
▣ Follicle Regulatory Protein (S) (FRP)	61
▣ GnRH-like Protein	64
▣ Insulin	66
■ Growth Hormone and Other Growth Factors and Their Possible Role in Ovulation	69
● Growth Hormone	69
● Other Growth Factors	77
▣ Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF)	78
▣ Insulin-Like Growth Factors (IGFs)	82
▣ Platelet Derived Growth Factor (PDGFs)	87
▣ Transforming Growth Factors (TGFs)	88
SUBJECTS AND METHODS	91
RESULTS	94
DISCUSSION	109
SUMMARY AND CONCLUSION	120
REFERENCES	124
ARABIC SUMMARY	

List of Abbreviations

A	Androstenedione
AVP	Arginine vasopressin
B-TGF	B-Transforming growth factor
BMI	Body mass index
CC	Clomiphene citrate
CL	Corpus luteum
CS	Chondroitin sulphate
DHT	Dihydrotestosterone
E ₂	Oestradiol
EGF	Epidermal growth factor
F.F.	Follicular fluid
F.G.F	Fibroblast growth factor
F.S.H	Follicle stimulating hormone
FRP	Follicle regulatory protein
GAGs	Glycosaminoglycans
GCs	Granulosa cells
GHIH	Growth hormone inhibitory hormone
GHRH	Growth hormone releasing hormone
GIFT	Gamete Intrafallopian transfer
GnRH	Gonadotrophin releasing hormone
hCG	Human chorionic gonadotrophins
hGH	Human growth hormone
hMG	Human menopausal gonadotrophin
HS	Heparin sulphate

IGF-I	Insulin-like growth factor -I
IVF	In vitro fertilization
LDL	Low density lipoprotein
LH	Luteinizing hormone
LHRH	Luteinizing hormone releasing hormone
MIS	Meiosis inducing substance
MPS	Meiosis preventing substance
MSA	Multiplication stimulating activity
OSCC	Oocyte corona cumulus complex
OMI	Oocyte maturation inhibitor
P ₄	Progesterone
PA	Plasminogen activators
PCO	Polycystic ovaries
PDGF	Platelet derived growth factor
PRL	Prolactin
RIA	Radioimmunoassay
SH	Somatotropic hormone
SMC	Somatomedin-c
T	Testosterone
TET	Tubal embryo transfer
VIP	Vasoactive intestinal peptide

INTRODUCTION



INTRODUCTION

Since the beginning of the recorded history the human race has placed emphasis on fertility. Nothing more vividly demonstrates the importance of fertility to the individual than the reaction by and to those who do not have children. The grief of a woman who has failed to bear a live-born child is no less in modern society than it was for our forefathers (**Lunenfeld and Insler, 1990**).

The number of couples seeking a fertility work up is increasing every year. Approximately 10-15% of all those trying to achieve pregnancy are infertile (**Speroff et al., 1989**). Ovulation failure is the primary defect in at least 20% of infertile couples (**Kase et al., 1990**).

Normal ovulation requires coordination of the menstrual system at all levels: the central hypothalamic-pituitary axis, the feed back signals, and local responses within the ovary. The

loss of ovulation may be due to any one of an assortment of factors operating at each of these levels. The end result is a dysfunctional state: anovulation (**Speroff et al., 1989**).

In the past a woman with ovulatory dysfunction had little hope of achieving a pregnancy. The successful therapy of this problem is one of the most dramatic advances in gynaecologic endocrinology. Today, if lack of ovulation is the only problem causing infertility, a persistent couple can expect their chances of conceiving to match the rate found in normal population (**Speroff et al., 1989**).

A number of treatment possibilities are prescribed for induction of ovulation including drugs as clomiphine citrate, bromocriptine, human menopausal gonadotrophin, human chorionic gonadotrophin, cortisol derivatives or gonadotrophin releasing hormone and its analogues (**Crowley and McArthur, 1980**). Surgical methods of induction of ovulation include wedge resection or laporoscopic cauterization of polycystic ovaries using either electrocautery or laser (**Adashi et al., 1981**).

A possible relationship between human growth hormone (hGH) and ovarian response to gonadotrophin is recently suggested. **Homburg et al. (1988)**, demonstrated that treatment


with hGH can augment the ovarian response to gonadotrophin stimulation in women with ovaries relatively resistant to human menopausal gonadotrophin therapy. These findings were confirmed by a case report by **Blumenfeld and Lunenfeld (1989)**, and by more recent trials by **Homburg et al. (1990)**; **Hugues et al. (1991)**; **Ibrahim et al. (1991)**. Yet, the findings of a recent study (**Stone and Marrs, 1991**), challenge the speculation that endogenous peripheral hGH content relate to ovarian responsiveness to F.S.H.

Menache et al. (1990) suggested the use of clonidine as a provocative test which may help to predict responsiveness to human menopausal gonadotrophin stimulation.

During the last few year, the importance of intraovarian regulation and potentiating effect of growth hormone (GH) and various growth factors on granulosa cell response to FSH has been demonstrated (**Advis et al., 1981**). The action of GH on the granulosa cells may be direct (**Jia et al., 1986**) or may occur via an increase in ovarian concentration or production of growth factors (**Daroven and Hsueh, 1986**).

These findings prompted us to assess whether the level of growth hormone reserve is correlated to the ovarian response to clomiphene citrate as a method of inducing ovulation in anovulatory infertile women.

AIM OF THE WORK




AIM OF THE WORK

The purpose of this work is:

- 1) To assess the clinical value of the use of clonidine (i.e. growth hormone release) as an adjuvant therapy for ovulation induction with clomiphene citrate.
- 2) To evaluate the possible role of growth hormone in modulation of ovarian function.

REVIEW OF LITERATURE



REVIEW OF LITERATURE

Methods of Ovulation Induction

Ovulation is still a mysterious phenomenon: its regulatory mechanism is poorly understood and its occurrence is difficult to detect. It is crucial for fertility and also has definite links to woman's health. A lack of or defective ovulation is one of the commonest causes of sterility in humans. Sometimes this is due to unfavourable conditions such as low body weight, excess prolactin or androgen, and once the problem has been corrected regular ovulatory cycles start again. However, the pathophysiology underlying most anovulation is still unknown and therefore no specific treatment can be prescribed for these patients. Nevertheless, the great advances in the study of ovarian physiology and the availability of powerful drugs allow an effective treatment today for the vast majority of anovulatory women (Crosignani, 1990).